What is Onureg, and how does it work?

Onureg is a prescription medicine used for continued treatment of adults with acute myeloid leukemia (AML) who:

  • had a first complete remission (CR) following intensive induction chemotherapy with or without recovery of your blood cell counts, and
  • who are not able to complete intensive curative therapy.

It is not known if Onureg is safe and effective in children under 18 years of age.

What are the side effects of Onureg?

Onureg can cause serious side effects, including:

  • New or worsening low white blood cell counts (neutropenia). New or worsening low white blood cell counts are common but can also be severe during treatment with Onureg. If your white blood cell counts become very low, you are at increased risk for infections. Your healthcare provider will check your white blood cell counts before and during treatment with Onureg. Your healthcare provider may prescribe a medicine to help increase your white blood cell count if needed.

Tell your healthcare provider right away if you get any of the following symptoms:

  • New or worsening low platelet counts (thrombocytopenia). Low platelet counts are common but can also be severe during treatment with Onureg. Your healthcare provider will check your platelet counts before and during treatment with Onureg. Tell your healthcare provider right away if you have any unusual bruising or bleeding. Your healthcare provider may change your dose or tell you to stop taking Onureg if you have low blood cell counts.

Onureg may cause fertility problems in males and females, which may affect your ability to have children. Talk with your healthcare provider if you have concerns about fertility.

The most common side effects of Onureg include:

These are not all of the possible side effects of Onureg. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is the dosage for Onureg?

Important Administration Information

Do not substitute Onureg for intravenous or subcutaneous azacitidine. The indications and dosing regimen for Onureg differ from that of intravenous or subcutaneous azacitidine.

Recommended Dosage

The recommended dosage of Onureg is 300 mg orally once daily with or without food on Days 1 through 14 of each 28-day cycle. Continue Onureg until disease progression or unacceptable toxicity.

Administer an antiemetic 30 minutes prior to each dose of Onureg for the first 2 cycles. Antiemetic prophylaxis may be omitted after 2 cycles if there has been no nausea and vomiting.

If the absolute neutrophil count (ANC) is less than 0.5 Gi/L on Day 1 of a cycle, do not administer Onureg. Delay the start of the cycle until the ANC is 0.5 Gi/L or more.

Instruct patients on the following:

  • Do not split, crush, or chew Onureg tablets.
  • Take a dose about the same time each day.
  • If a dose of Onureg is missed, or not taken at the usual time, take the dose as soon as possible on the same day, and resume the normal schedule the following day. Do not take 2 doses on the same day.
  • If a dose is vomited, do not take another dose on the same day. Resume the normal schedule the following day.

Onureg is a hazardous drug. Follow applicable special handling and disposal procedures.1

Monitoring And Dosage Modifications For Adverse Reactions

Monitor complete blood count every other week for the first 2 cycles and prior to the start of each cycle thereafter. Increase monitoring to every other week for the 2 cycles after any dose reduction for myelosuppression.

The recommended dosage modifications for adverse reactions are provided in Table 1.

Table 1: Recommended Dosage Modifications for Adverse Reactions

Adverse ReactionSeverityRecommended Dosage Modification
MyelosuppressionNeutrophils less than 0.5 Gi/L on Cycle Day 1Interrupt treatment. Resume at the same dose once neutrophils return to 0.5 Gi/L or higher.
Neutrophils less than 1 Gi/L with fever at anytimeFirst Occurrence
  • Interrupt treatment. Resume at the same dose once neutrophils return to 1 Gi/L or higher.
Occurrence in 2 Consecutive Cycles
  • Interrupt treatment. After neutrophils return to 1 Gi/L or higher, resume at reduced dose of 200 mg.
  • If a patient continues to experience febrile neutropenia after dose reduction, reduce the treatment duration by 7 days.
  • If febrile neutropenia reoccurs after dose and schedule reduction, discontinue Onureg.
Platelets less than 50 Gi/L with bleedingFirst Occurrence
  • Interrupt dose. Resume at the same dose once platelets return to 50 Gi/L or higher.
Occurrence in 2 Consecutive Cycles
  • Interrupt dose. After platelets return to 50 Gi/L or higher, resume at reduced dose of 200 mg.
  • If a patient continues to experience thrombocytopenia with bleeding after dose reduction, reduce the treatment duration by 7 days.
  • If thrombocytopenia with bleeding reoccurs after dose and schedule reduction, discontinue Onureg.
Gastrointestinal Toxicity Grade 3 or 4 Nausea or Vomiting
  • Interrupt dose. Resume at the same dose once toxicity has resolved to Grade 1 or lower.
  • If toxicity reoccurs, interrupt dose until resolved to Grade 1 or lower. Resume at reduced dose of 200 mg.
  • If a patient continues to experience the toxicity after dose reduction, reduce the treatment duration by 7 days.
  • If the toxicity continues or reoccurs after dose and schedule reduction, discontinue Onureg.
Grade 3 or 4 Diarrhea
  • Interrupt dose. Resume at the same dose once toxicity has resolved to Grade 1 or lower.
  • If toxicity reoccurs, interrupt dose until resolved to Grade 1 or lower. Resume at reduced dose of 200 mg.
  • If a patient continues to experience the toxicity after dose reduction, reduce the treatment duration by 7 days.
  • If the toxicity continues or reoccurs after dose and schedule reduction, discontinue Onureg.
Other Adverse Reactions Grade 3 or 4
  • Interrupt dose and provide medical support. Resume at the same dose once toxicity has resolved to Grade 1 or lower.
  •   If toxicity re-occurs, interrupt dose until resolved to Grade 1 or lower. Resume at reduced dose of 200 mg.
  • If a patient continues to experience the toxicity after dose reduction, reduce the treatment duration by 7 days.
  • If the toxicity continues or reoccurs after dose and schedule reduction, discontinue Onureg.

SLIDESHOW

Signs of Cancer in Men: Could it Be Cancer? See Slideshow

What drugs interact with Onureg?

No Information Provided

Is Onureg safe to use while pregnant or breastfeeding?

  • Based on its mechanism of action and findings in animals, Onureg can cause fetal harm when administered to a pregnant woman.
  • There are no available data on Onureg use in pregnant women to evaluate for a drug-associated risk.
  • There are no data regarding the presence of azacitidine in human milk or the effects on the breastfed child or milk production.
  • Because of the potential for serious adverse reactions in the breastfed child, advise women not to breastfeed during treatment with Onureg and for 1 week after the last dose.

Summary

Onureg is a prescription medicine used for continued treatment of adults with acute myeloid leukemia (AML) who had a first complete remission (CR) following intensive induction chemotherapy with or without recovery of your blood cell counts, and who are not able to complete intensive curative therapy.

Treatment & Diagnosis

Medications & Supplements

QUESTION

What is leukemia? See Answer

Health Solutions From Our Sponsors

FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Medically Reviewed on 10/14/2020
References
All sections courtesy of the U.S. Food and Drug Administration
CONTINUE SCROLLING FOR RELATED SLIDESHOW